title: Combined hormone therapy and radiation therapy for locally advanced prostate cancer.
abstract: The combination of radiotherapy and androgen suppression with luteinizing hormone releasing hormone agonist has become a standard of care for locally advanced prostate cancer. Phase III randomized trials have shown that for locally advanced prostate cancer a 4-month complete androgen blockade initiated 2 months prior radiotherapy and stopped at the completion of radiotherapy increased overall survival in patients with Gleason score 2-6, meanwhile an adjuvant long term androgen suppression (2.5-3 years) improved significantly overall survival.
authors.affiliation: Radiation Oncology Department, C.H.U. Michallon, Grenoble cedex 9, France MBolla@chu-grenoble.fr
authors.forename: M
authors.initials: M
authors.lastname: Bolla
authors.forename: M
authors.initials: M
authors.lastname: Laramas
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008297:Male; D011467:Prostate / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal